Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform

Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the filing of a provisional patent application covering a ...
Yahoo Finance

Vector Science and Therapeutics Announces Listing on the TSX Venture Exchange

Vancouver, British Columbia--(Newsfile Corp. - April 24, 2026) - Vector Science and Therapeutics Corp. (TSXV: PAIN) (formerly OpenSesame Acquisition Corp.) ("Vector" or the "Company") is pleased to ...
Yahoo Finance

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations MEQUON, Wis., May 13, 2026 /PRNewswire/ -- Vector Science & Therapeutics ...
Morningstar

Vector Science & Therapeutics Announces Tommy Thompson as Chairman of the Board

Former Wisconsin Governor and U.S. Secretary of Health and Human Services Brings Extensive Healthcare Leadership to Pioneer of Transdermal Drug Delivery Technology MEQUON, Wis., April 30, 2026 ...
Morningstar

Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor

MEQUON, Wis., June 8, 2026 /PRNewswire/ -- Vector Science & Therapeutics Corp. (TSXV: PAIN) today announced the appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board ...
Yahoo Finance

Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform

14-Year MLB Veteran and 2016 World Series Champion Joins Valor, Vector's Athlete Platform, to Make Sure the Next Generation Plays Longer and Hurts Less MEQUON, Wis., June 12, 2026 /PRNewswire/ -- ...
FinanzNachrichten.de

Vector Sciences & Therapeutics: Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform

Proprietary Magnetic Patch System Delivers Regenerative Peptides to Targeted Tissue Without Injection, with Built-In Confirmation of Successful Delivery MEQUON, Wis., June 30, 2026 /PRNewswire/ -- ...
Newswire

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Option agreement Supports Vector's Entry into the $80.8 Billion Peptide Market with 22 Novel Pharmaceutical-Grade Formulations FDA-Registered, cGMP Manufacturing-- MPP operates a modern 35,000 sq. ft.